Abstract
Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways leading to nickel-induced COX-2 expression are not well understood. In the current study, we found that the exposure of Beas-2B cells to nickel compounds resulted in the activation of both nuclear factor of activated T cell (NFAT) and nuclear factor- κB (NF-κB). The expression of COX-2 induced upon nickel exposure was inhibited by either a NFAT pharmacological inhibitor or the knockdown of NFAT3 by specific siRNA. We further found that the activation of NFAT and NF-κB was dependent on each other. Since our previous studies have shown that NF-κB activation is critical for nickel-induced COX- 2 expression in Beas-2B cells exposed to nickel compounds under same experimental condition, we anticipate that there might be a cross-talk between the activation of NFAT and NF-κB for the COX-2 induction due to nickel exposure in Beas-2B cells. Furthermore, we showed that the scavenging of reactive oxygen species (ROS) by introduction of mitochondrial catalase inhibited the activation of both NFAT and NF-κB, and the induction of COX-2 due to nickel exposure. Taken together, our results defining the evidence showing a key role of the cross-talk between NFAT and NF- κB pathways in regulating nickel-induced COX-2 expression, further provide insight into the understanding of the molecular mechanisms linking nickel exposure to its lung carcinogenic effects.
Keywords: Beas-2B cells, COX-2, nickel, NFAT, NF-κB, ROS, activator protein-1, dichlorofluorescein diacetate, Cyclosporine A, mouse embryonic fibroblasts, sodium dodecyl sulfate, vascular endothelial growth factor, urokinase-type plasminogen activator
Current Cancer Drug Targets
Title: A Cross-Talk Between NFAT and NF-κB Pathways is Crucial for Nickel- Induced COX-2 Expression in Beas-2B Cells
Volume: 11 Issue: 5
Author(s): T. Cai, X. Li, J. Ding, W. Luo, J. Li and C. Huang
Affiliation:
Keywords: Beas-2B cells, COX-2, nickel, NFAT, NF-κB, ROS, activator protein-1, dichlorofluorescein diacetate, Cyclosporine A, mouse embryonic fibroblasts, sodium dodecyl sulfate, vascular endothelial growth factor, urokinase-type plasminogen activator
Abstract: Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways leading to nickel-induced COX-2 expression are not well understood. In the current study, we found that the exposure of Beas-2B cells to nickel compounds resulted in the activation of both nuclear factor of activated T cell (NFAT) and nuclear factor- κB (NF-κB). The expression of COX-2 induced upon nickel exposure was inhibited by either a NFAT pharmacological inhibitor or the knockdown of NFAT3 by specific siRNA. We further found that the activation of NFAT and NF-κB was dependent on each other. Since our previous studies have shown that NF-κB activation is critical for nickel-induced COX- 2 expression in Beas-2B cells exposed to nickel compounds under same experimental condition, we anticipate that there might be a cross-talk between the activation of NFAT and NF-κB for the COX-2 induction due to nickel exposure in Beas-2B cells. Furthermore, we showed that the scavenging of reactive oxygen species (ROS) by introduction of mitochondrial catalase inhibited the activation of both NFAT and NF-κB, and the induction of COX-2 due to nickel exposure. Taken together, our results defining the evidence showing a key role of the cross-talk between NFAT and NF- κB pathways in regulating nickel-induced COX-2 expression, further provide insight into the understanding of the molecular mechanisms linking nickel exposure to its lung carcinogenic effects.
Export Options
About this article
Cite this article as:
Cai T., Li X., Ding J., Luo W., Li J. and Huang C., A Cross-Talk Between NFAT and NF-κB Pathways is Crucial for Nickel- Induced COX-2 Expression in Beas-2B Cells, Current Cancer Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/156800911795656001
DOI https://dx.doi.org/10.2174/156800911795656001 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Progress of Selective Fluorescent Chemosensors by Boronic Acid
Current Medicinal Chemistry Nano-antibiotics: A Therapeutic Future
Nanoscience & Nanotechnology-Asia Viral Disorder or Disordered Viruses: Do Viral Proteins Possess Unique Features?
Protein & Peptide Letters Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism Rapid Biosynthesis of Gold Nanoparticles Using Aqueous-ethanoic Leaf Extract of Heartleaf Moonseed: Characterization and Effect of pH on its Synthesis
Current Nanomaterials Synthesis, Structure and Application of α, β Dehydro-α-aminophosphonic and α,β-Dehydro-α-aminophosphinic Acid Derivatives
Current Organic Synthesis TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Mechanism of Action and Potential Use of Tamoxifen in the Treatment of Acute Mania
Current Psychopharmacology Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Current Signal Transduction Therapy Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Editorial (Hot Topic: Targeted Therapies in the Treatment of Breast Cancer and Localized Sarcomas)
Current Medicinal Chemistry The CLCA Gene Family A Novel Family of Putative Chloride Channels
Current Genomics Molecular Modeling Investigation of Folic Acid Conjugation to MDM2 Inhibitors for Enhanced Cellular Uptake and Target Binding
Current Computer-Aided Drug Design Implication of Disulfide Bridge Induced Thermal Reversibility, Structural and Functional Stability for Luciferase
Protein & Peptide Letters Overview of Naphthalimide Analogs as Anticancer Agents
Current Medicinal Chemistry Nanoparticles, Promising Carriers in Drug Targeting: A Review
Current Drug Therapy Learning from Nature: Bioinspired Strategies Towards Antimicrobial Nanostructured Systems
Current Topics in Medicinal Chemistry Patent Selection:
Recent Patents on Nanotechnology Meet Our Editorial Board Member
Current Cancer Drug Targets